Mobic Market Share Doubles Following Vioxx Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott's non-steroidal anti-inflammatory drug Mobic (meloxicam) is showing strong growth in the wake of the withdrawal of Merck's Vioxx, Verispan data released Oct. 13 show
You may also be interested in...
Mobic Generic Competition Possible In Early 2006
Boehringer Ingelheim brand rings up $293 mil. in first quarter sales as biggest beneficiary from COX-2 safety issues. Mobic loses exclusivity April 13, although generics are unlikely to enter the market for at least nine months.
Mobic Generic Competition Possible In Early 2006
Boehringer Ingelheim brand rings up $293 mil. in first quarter sales as biggest beneficiary from COX-2 safety issues. Mobic loses exclusivity April 13, although generics are unlikely to enter the market for at least nine months.
Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.